Hot Features
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I di... Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 1.47 | 8.01963993453 | 18.33 | 19.8 | 16.77 | 474606 | 17.78805174 | CS |
| 4 | 1.35 | 7.31707317073 | 18.45 | 20.19 | 16.41 | 561043 | 18.10023605 | CS |
| 12 | -3.68 | -15.6729131175 | 23.48 | 24.08 | 16.41 | 703687 | 19.64889612 | CS |
| 26 | -20.83 | -51.2675363032 | 40.63 | 44.6 | 13.5 | 761149 | 21.32951008 | CS |
| 52 | 7.89 | 66.2468513854 | 11.91 | 44.6 | 8.91 | 527243 | 22.34692304 | CS |
| 156 | 9.7796 | 97.5969023193 | 10.0204 | 44.6 | 5.83 | 232659 | 19.64108212 | CS |
| 260 | 9.7796 | 97.5969023193 | 10.0204 | 44.6 | 5.83 | 139335 | 19.64108212 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.